VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia

Sponsor
London Vision Clinic (Other)
Overall Status
Unknown status
CT.gov ID
NCT02528123
Collaborator
(none)
187
1
1
53
3.5

Study Details

Study Description

Brief Summary

The purpose of this study is to validate the safety and effectiveness of treating myopia (short-sightedness) higher than -10D using small incision lenticule extraction (SMILE) with the VisuMax femtosecond laser.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Small incision lenticule extraction
  • Drug: Tobramycin and dexamethasone
  • Drug: Ofloxacin
  • Drug: Proxymetacaine 0.5%
  • Drug: Oxybuprocaine 0.4%
N/A

Detailed Description

Laser refractive surgery (LASIK and PRK) has been established for 25 years to treat myopia (short-sightedness). Over this time, the technology has been significantly improved to enable safe treatment of myopia up to -15D. Improvements including changing the shape of the lens of corneal tissue removed to better match the natural shape, and increasing the diameter of the applied correction to cover larger pupil sizes, have greatly reduced side-effects such as night vision glare and halos. Similarly, safety has been improved by using a laser (femtosecond laser) to create the corneal flap rather than a blade (known as a microkeratome), meaning that the cornea is reliably left with more than the safe amount of tissue.

In 2006, a new method of laser refractive surgery was introduced, small incision lenticule extraction (SMILE), which provides a minimally invasive keyhole method as it avoids the need to create a flap. In SMILE, a single laser (femtosecond laser) is used to make two curved cuts inside the cornea (without breaching the outside) that separate the lens of tissue that needs removing to focus the vision. This lens of tissue is removed in once piece (rather than evaporated as in LASIK) through a small 2mm wide tunnel to the surface.

SMILE has been used to treat short-sightedness up to -10D for more than 200,000 procedures worldwide and has been shown to achieve similar results to LASIK. However, because no flap is needed, this upper part of the cornea can also contribute strength, meaning that the cornea is stronger after SMILE than after LASIK. It is also expected that the accuracy for higher corrections using SMILE would be better than LASIK because the potential inaccuracies associated with excimer lasers (used in LASIK) are eliminated. This study will investigate the results of SMILE for myopia above -10D.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
187 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia
Study Start Date :
Apr 1, 2016
Anticipated Primary Completion Date :
Sep 1, 2020
Anticipated Study Completion Date :
Sep 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Small incision lenticule extraction

Patients with high myopia will undergo a SMILE procedure to correct their refraction. Proxymetacaine 0.5% and Oxybuprocaine 0.4% will be used as anaesthetic during the procedure. Tobramycin and dexamethasone, and ofloxacin will be used four times a day for one week after the procedure.

Procedure: Small incision lenticule extraction
The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
Other Names:
  • ReLEx smile
  • SMILE
  • Drug: Tobramycin and dexamethasone
    Tobramycin and dexamethasone (Tobradex) eye drops will be used four times a day for 1 week after the procedure

    Drug: Ofloxacin
    Ofloxacin (Exocin) eye drops will be used four times a day for 1 week after the procedure

    Drug: Proxymetacaine 0.5%
    Proxymetacaine 0.5% eye drops will be used as an anaesthetic during the procedure

    Drug: Oxybuprocaine 0.4%
    Oxybuprocaine 0.4% eye drops will be used as an anaesthetic during the procedure

    Outcome Measures

    Primary Outcome Measures

    1. Variability of the refractive predicatibility (standard deviation of the postoperative spherical equivalent, adjusted relative to the intended target, after the SMILE procedure) [1 year]

      Calculate the standard deviation of the postoperative spherical equivalent, adjusted relative to the intended target, after the SMILE procedure

    Secondary Outcome Measures

    1. Efficacy of uncorrected distance visual acuity [1 year]

      Measure the uncorrected distance visual acuity achieved after the SMILE procedure relative to the preoperative CDVA for all eyes where the intended target refraction was emmetropia

    2. Safety of corrected distance visual acuity (change in corrected distance visual acuity) [1 year]

      Assess the change in corrected distance visual acuity (CDVA) before and after the SMILE procedure

    3. Predictability of refractive correction [1 year]

      Measure the postoperative refraction and calculate the deviation from the intended target in terms of spherical equivalent. Mean, standard deviation and range will be calculated. The data will also be analyzed as a scatter plot by plotting the attempted vs achieved spherical equivalent refraction. The data will also be graphically displayed as a histogram.

    4. Predictability of refractive astigmatism correction [1 year]

      Measure the postoperative refractive astigmatism and calculate the deviation from the intended target. Mean, standard deviation and range will be calculated. The data will also be analyzed as a scatter plot by plotting the target induced astigmatism vs the surgically induced astigmatism. The data will also be graphically displayed as a histogram.

    5. Stability of the spherical equivalent refraction [1 day, 1 month, 3 months, and 1 year]

      Measure the postoperative refraction at 1 day, 1 month, 3 months, and 12 months after the SMILE procedure and calculate the mean and standard deviation of spherical equivalent refraction for each time point.

    6. Change in night vision disturbances (questionnaire) [1 year]

      Provide the patient with a questionnaire to subjectively grade their quality of vision at night to assess whether this has changed after the SMILE procedure

    7. Change in corneal higher order aberrations [1 year]

      Measure the corneal aberrations before and after the SMILE procedure using the Atlas topographer to evaluate the change in corneal aberrations due to the surgery

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    Only patients who are medically suitable for corneal refractive surgery can be included in the study.

    • Subjects should be 21 years of age or older

    • Eyes with high myopia spherical equivalent between -9.00 D up to -14.00 D, with cylinder up to 7.00 D

    • The corrected distance visual acuity will be 20/40 or better in each eye pre-operatively

    • Calculated sub-lenticule thickness (SLT) ≥220 µm

    • Calculated total uncut stromal thickness (TUST) ≥300 µm

    • Contact lens wearers must stop wearing their contact lenses at least four weeks per decade of wear before baseline measurements in case of hard contact lenses and one week before baseline measurements in case of soft contact lenses.

    • Patient will be able to understand the patient information and willing to sign an informed consent

    • Patient will be willing to comply with all follow-up visits and the respective examinations as specified in the flow-chart

    Exclusion Criteria:
    • Previous intraocular or corneal surgery of any kind on the eye being treated

    • Patient not being able to lie flat in a horizontal position

    • Patient not being able to tolerate local or topical anesthesia

    • Autoimmune diseases

    • Sicca syndrome, dry eye

    • Herpes viral (herpes simplex) infections

    • Herpes zoster

    • Diabetes

    • Pregnant or nursing women (or who are planning pregnancy during the study)

    • Patients with a weight of > 135 kg

    • Any residual, recurrent or acute ocular disease or abnormality of the eye, e.g.

    • Cataract

    • Suspected glaucoma or an intraocular pressure > 21 mm of Hg

    • Corneal disease

    • Corneal thinning disorder, e.g. keratoconus,

    • Pellucid marginal corneal degeneration

    • Dystrophy of the basal membrane

    • Corneal oedema

    • Exudative macular degeneration

    • Infection

    • Any residual, recurrent, or active abnormality of the cornea to be treated, e.g.

    • Existing corneal implant

    • Corneal lesion

    • Unstable refraction

    • Connective tissue disease

    • Dry eye

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 London Vision Clinic London United Kingdom W1G 7LA

    Sponsors and Collaborators

    • London Vision Clinic

    Investigators

    • Principal Investigator: Dan Z Reinstein, MD MA, London Vision Clinic

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Dan Reinstein, Medical Director, London Vision Clinic
    ClinicalTrials.gov Identifier:
    NCT02528123
    Other Study ID Numbers:
    • LoVC-004
    First Posted:
    Aug 19, 2015
    Last Update Posted:
    Feb 25, 2020
    Last Verified:
    Feb 1, 2020
    Keywords provided by Dan Reinstein, Medical Director, London Vision Clinic
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 25, 2020